全文获取类型
收费全文 | 21375篇 |
免费 | 1781篇 |
国内免费 | 744篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 206篇 |
妇产科学 | 403篇 |
基础医学 | 1785篇 |
口腔科学 | 1353篇 |
临床医学 | 1202篇 |
内科学 | 1893篇 |
皮肤病学 | 137篇 |
神经病学 | 659篇 |
特种医学 | 1340篇 |
外国民族医学 | 2篇 |
外科学 | 886篇 |
综合类 | 2893篇 |
现状与发展 | 2篇 |
预防医学 | 1069篇 |
眼科学 | 1189篇 |
药学 | 4651篇 |
12篇 | |
中国医学 | 2734篇 |
肿瘤学 | 1393篇 |
出版年
2024年 | 44篇 |
2023年 | 350篇 |
2022年 | 560篇 |
2021年 | 927篇 |
2020年 | 750篇 |
2019年 | 671篇 |
2018年 | 708篇 |
2017年 | 721篇 |
2016年 | 803篇 |
2015年 | 921篇 |
2014年 | 1382篇 |
2013年 | 1435篇 |
2012年 | 1451篇 |
2011年 | 1498篇 |
2010年 | 1173篇 |
2009年 | 1003篇 |
2008年 | 1011篇 |
2007年 | 1111篇 |
2006年 | 867篇 |
2005年 | 797篇 |
2004年 | 677篇 |
2003年 | 633篇 |
2002年 | 509篇 |
2001年 | 496篇 |
2000年 | 419篇 |
1999年 | 365篇 |
1998年 | 266篇 |
1997年 | 216篇 |
1996年 | 222篇 |
1995年 | 179篇 |
1994年 | 194篇 |
1993年 | 149篇 |
1992年 | 158篇 |
1991年 | 170篇 |
1990年 | 174篇 |
1989年 | 109篇 |
1988年 | 124篇 |
1987年 | 101篇 |
1986年 | 67篇 |
1985年 | 91篇 |
1984年 | 73篇 |
1983年 | 61篇 |
1982年 | 60篇 |
1981年 | 47篇 |
1980年 | 42篇 |
1979年 | 36篇 |
1978年 | 25篇 |
1977年 | 15篇 |
1976年 | 9篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
3.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献4.
目的建立环境水样中痕量铜的浊点萃取(cloud point extraction,CPE)-火焰原子吸收光谱(flame atomic absorption spectrometry,FAAS)测定法。方法样品在p H 9.5的条件下,加入0.4 ml的1 mmol/L 2-(5-溴-2-吡啶偶氮)-5-二乙氨基酚(5-Br-PADAP)溶液,0.1%氯化钙溶液0.1 ml,5%(W/V)Triton X-114溶液0.8 ml,40℃加热15 min后离心,采用火焰原子吸收光谱法进行检测。结果在2~240μg/L的线性范围内,所得回归方程为A=0.002 7c+0.024 6,r=0.995 8。以3倍信噪比计算,方法的检出限为0.62μg/L,富集倍数为36.58倍,平均加标回收率为96.28%~98.08%,RSD为1.67%~3.13%。结论该方法简单、灵敏,具有良好的重现性,适用于环境水样中痕量铜的测定。 相似文献
5.
随着腔镜技术的进一步发展以及微创理念应用于结直肠外科疾病的诊治中,结直肠相关疾病的诊治发生了翻天覆地的变化。由传统的经腹手术到腹腔镜手术、经自然腔道手术,再到经自然腔道取标本手术(NOSES),结直肠疾病的外科诊治在微创领域取得了巨大成果。NOSES技术是目前结直肠外科在微创领域前沿的手术方式之一,它通过经直肠、阴道取标本来避免了腹壁的辅助取标本切口,从而将结直肠外科手术进一步微创化。NOSES技术集传统腹腔镜手术的优势与现代微创外科的理念于一体,它在确保手术效果的基础上集中体现了微创、加速康复外科、功能外科、"无疤"等理念的特点。本文主要就国内外各中心开展NOSES技术在结直肠外科诊治开展中的相关经验、心得和体会进行综述。 相似文献
6.
7.
8.
目的:通过对同一患者双眼不同手术方式的自身对比,了解飞秒扫描后改SBK手术的疗效差异,为不同患者屈光手术方式的选择提供临床指导依据。方法回顾分析2例右眼行飞秒激光小切口透镜取出术( SMILE),左眼SMILE术中负压环脱失和激光扫描不良透镜分离困难而改行机械刀制瓣准分子激光手术( SBK)的患者,比较术后视力、等效球镜( SE)、对比敏感度( CSF)、波前像差( HAOS)以及泪膜破裂时间( BUT)、泪液分泌功能试验( Schimer I)和SPEED、OSDI干眼症状问卷调查分析差异。结果(1)术后个月,均能达到最佳矫正视力(BSCVA),等效球镜均在±0.75 D以内,双眼比较无显著性差异。(2)CSF的比较,左右眼无显著性差异,略低于正常水平。(3)术后3个月,BUT和Schimer检查中,双眼无显著性差异。(4)HAOS比较中,总像差RMS和高阶像差这两项, SMILE眼低于SBK眼;球差(S)的比较,SMILE眼高于SBK眼。(5)SPEED和OSDI问卷评分双眼无显著差异。结论 SMILE失败眼改SBK后视觉质量与SMILE眼无显著差异,其视觉质量、疗效不受影响。 相似文献
9.
10.
《Journal of pharmaceutical sciences》2019,108(7):2500-2504
Accurately predicting the hepatic clearance of compounds using in vitro to in vivo extrapolation (IVIVE) is crucial within the pharmaceutical industry. However, several groups have recently highlighted the serious error in the process. Although empirical or regression-based scaling factors may be used to mitigate the common underprediction, they provide unsatisfying solutions because the reasoning behind the underlying error has yet to be determined. One previously noted trend was intrinsic clearance-dependent underprediction, highlighting the limitations of current in vitro systems. When applying these generated in vitro intrinsic clearance values during drug development and making first-in-human dose predictions for new chemical entities though, hepatic clearance is the parameter that must be estimated using a model of hepatic disposition, such as the well-stirred model. Here, we examine error across hepatic clearance ranges and find a similar hepatic clearance-dependent trend, with high clearance compounds not predicted to be so, demonstrating another gap in the field. 相似文献